Pharma BD Deal Intelligence

Aventis Pharma AG / Millennium Pharmaceuticals Inc.

2000 · Co-Development · $450M · Complete

Announcement Sentiment

Strongly positive

Aventis-Millennium 'groundbreaking' five-year alliance to discover, develop and co-market anti-inflammatory drugs. $250M equity investment (~2.5% stake) plus $200M in research fees over five years. First biotech-pharma deal on truly equal terms — 50/50 cost and US profit share.

Did it work? Outcome assessment

Strategic verdict

Failed to Achieve

Financial impact

Dilutive

Pipeline outcome

Assets Terminated

Assessment window: 5yr post-close.

Key facts

Announced Jun 23, 2000
Closed Jun 23, 2000
Deal value $450M
Deal type Co-Development
Therapeutic area Rheumatoid arthritis, asthma, allergies
Indications Rheumatoid arthritis, asthma, allergies
Key assets Inflammation pipeline (multiple discovery-stage)
Mechanism Genomics-derived anti-inflammatory targets

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals